Is the combination of resmetirom and semaglutide useful for the treatment of metabolic dysfunction‐associated steatohepatitis?

Documenti analoghi

• Hepatic thyroid hormone receptor‐β signalling: Mechanisms and recent advancements in the treatment of metabolic dysfunction‐associated steatohepatitis
  di: Stergios A. Polyzos, et al.
  Pubblicazione: (2024)
• The US Food and Drug administration has approved resmetirom as the first drug to treat metabolic dysfunction‐associated steatohepatitis (MASH)
  di: Iskandar Idris
  Pubblicazione: (2024)
• The effects of anti‐obesity medications on bone metabolism: A critical appraisal
  di: Athanasios D. Anastasilakis, et al.
  Pubblicazione: (2025)
• A review of multidisciplinary care in metabolic dysfunction‐associated steatohepatitis and cardiometabolic disease, with a focus on Canada
  di: James Kim, et al.
  Pubblicazione: (2025)
• Efsubaglutide Alfa attenuates metabolic dysfunction‐associated steatohepatitis in mice with improvements in second harmonic generation‐derived fibrosis features
  di: Yahao Wang, et al.
  Pubblicazione: (2026)